• About
  • Advertise
  • Careers
Tuesday, December 5, 2023
  • Login
No Result
View All Result
Hindustan Surkhiyan
41 °f
New York County
  • World
  • USA
  • New York
  • Bangladesh
  • India
  • Sports
  • Entertainment
  • Science & Tech
  • More
    • Opinion
    • Fashion
    • Business & Economy
    • Interview
    • Literature
      • poetry
    • Lifestyle
      • Biography
    • Nature
    • Travels
    • Cartoons
  • বাংলা
  • World
  • USA
  • New York
  • Bangladesh
  • India
  • Sports
  • Entertainment
  • Science & Tech
  • More
    • Opinion
    • Fashion
    • Business & Economy
    • Interview
    • Literature
      • poetry
    • Lifestyle
      • Biography
    • Nature
    • Travels
    • Cartoons
  • বাংলা
No Result
View All Result
Hindustan Surkhiyan
Home World

New data shows Alzheimer’s drug can slow cognitive decline

November 30, 2022
in World
Reading Time: 2 mins read
A A
New data shows Alzheimer’s drug can slow cognitive decline
0
VIEWS
Share on FacebookShare on Twitter

Promising data shows that an Alzheimer’s drug can slow cognitive decline.

In a phase III clinical trial, with results published Tuesday in the New England Journal of Medicine, the drug, Lecanemab — developed by Eisai and Biogen Inc. — slowed the rate of cognitive decline by 27% in patients in the early stages of the disease, making it the first drug of its kind to produce such positive trial results, the study showed.

“Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in less decline than placebo on all measures of cognition and function at 18 months,” said Dr. Christopher Van Dyck, director of the Yale Alzheimer’s Disease Research Center, during his presentation of trial efficacy results at the Clinical Trials on Alzheimer’s Disease meeting, held in San Francisco.

Researchers followed nearly 1,800 patients over the course of 18 months and found the drug “resulted in moderately less decline on measures of cognition and function,” compared to patients who received a placebo.

However, the companies noted that “longer trials are warranted to determine the efficacy and safety of Lecanemab in early Alzheimer’s disease.”

Patients who have Alzheimer’s disease have build-up of two proteins, amyloid-beta and tau, in the brain. They clump together and form plaques, disrupting cell function and causing symptoms such as memory loss and confusion.

Lecanemab is a monoclonal antibody that helps remove the amyloid-beta clumps.

Trial participants were split into two groups, both with a Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score of about 3.2 when the trial began. This score, which measures dementia impairment, has a scale from 0 indicating no impairment to 18.0 indicating severe impairment. A score of 3.2 indicates very mild impairment.

Over the course of 18 months, patients in the Lecanemab group saw their score go up by 1.21 points in comparison with patients in the placebo group, who saw their score go up by 1.66 points.

Previous Post

US approves $1 billion arms sale to Qatar

Next Post

Bengal Ex-Minister, Close Aid’s Judicial Custody Extended Till December 14

Related Posts

Gaza’s poor sanitation ‘perfect storm for tragedy’

Gaza’s poor sanitation ‘perfect storm for tragedy’

November 21, 2023
Why Maldives leader wants Indian troops out of nation?

Why Maldives leader wants Indian troops out of nation?

November 21, 2023
Russia holds joint naval drills with India

Russia holds joint naval drills with India

November 21, 2023
Sheikh Hasina Opens Dohazari-Cox’s Bazar Rail Line

Sheikh Hasina Opens Dohazari-Cox’s Bazar Rail Line

November 11, 2023
Next Post
Bengal Minister Arrested Day After ₹ 20 Crore Cash Found At Aide’s Home

Bengal Ex-Minister, Close Aid's Judicial Custody Extended Till December 14

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Most Recent

Tunnel rescue hits fresh hurdle in its final stretch

Tunnel rescue hits fresh hurdle in its final stretch

November 24, 2023
Why anti-India sentiments are growing in Bangladesh: The Times of India

Why anti-India sentiments are growing in Bangladesh: The Times of India

November 24, 2023
Australian openers vie for attention in Pakistan warm-up

Australian openers vie for attention in Pakistan warm-up

November 23, 2023
US thwarts plot to kill Sikh separatist

US thwarts plot to kill Sikh separatist

November 23, 2023
BJP-Backed Candidates Win Polls To 2 Civic Bodies In Goa

New BJP Banner On X Has PM Modi, JP Nadda Against Ram Temple Backdrop

November 23, 2023

Follow Us

Shah J. Choudhury
President
Husneara Choudhury
Editor
A Unit of Shah Group
USA Office: 70-52 Broadway 1A, Jackson Heights, NY 11372. Contact:‭ +1 (212) 920-0700.
Bangladesh Office: F-29, Road-01, Sector-02, Aftabnagar, Dhaka-1212.
India Office: 352, Block A, Sector 2, Rohini, New Delhi 110085. Contact: +91 987 343 8786.
Email: hindustansurkhiyan@gmail.com, www.hindustansurkhiyan.com

A Unit of Shah Group
© Copyright 2022, All Rights Reserved by Hindustan Surkhiyan
Privacy Policy   Term & Conditions
No Result
View All Result
  • World
  • USA
  • New York
  • Bangladesh
  • India
  • Sports
  • Entertainment
  • Science & Tech
  • More
    • Opinion
    • Fashion
    • Business & Economy
    • Interview
    • Literature
      • poetry
    • Lifestyle
      • Biography
    • Nature
    • Travels
    • Cartoons
  • বাংলা

© Copyright 2022, All Rights Reserved by Hindustan Surkhiyan

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.